 |
 How To Triple Your Money In A Single Stock! by Robert Morris, Editor I spent most of this past weekend at my home away from home... one of the Phoenix area's many softball fields. You see, my 10-year old daughter is playing her first season of club softball. And every other weekend, our family, along with hundreds of others, camp out at the ball field to watch our kids play. This weekend the team was playing in yet another local tournament. But it turned out to be one of the more exciting ones for my family. -------------Sponsor------------- Free Report – Stock Picks Included! This brand new must-have, report is called The Top 10 Stocks You Should Buy Right Now. In it, you'll find 10 investment recommendations from three of the industry's most highly respected advisors. Normally, investment recommendations from these experts would cost you hundreds of dollars. But not today... For the next 10-days, you have the opportunity to get this report absolutely FREE! ------------------------------------ In her first at bat in the very first game, my daughter cranked a fastball into deep centerfield. The poor little outfielder had to chase the ball all the way to the fence. And before she could get the ball back into the infield, my daughter was standing on third for a stand-up triple! (I think she could have scored a homerun, but the third-base coach held her up to avoid a close play at the plate.) My daughter made it look really easy... But let me tell you, playing at this level is anything but easy. Like anything in life, it takes hours of practice and hard work to do something really well. And the same goes for investing. You're not going to hit too many triples in the stock market unless you spend some time doing your homework. You have to follow the market on a regular basis. And you have to do hours of tedious research to uncover the hidden gems. Here's a perfect example... Back in June of last year, I was researching biotechnology stocks to find a trade for subscribers of my Biotech Supertrader service. I do this research on a regular basis as I usually recommend two biotech stocks every month. I saw on the FDA calendar that Threshold Pharmaceuticals (THLD) was expected to release important clinical trial results in the first quarter of 2012. The company was conducting a phase 2 clinical trial of their novel anti-cancer drug, TH-302, in patients with pancreatic cancer. Now, I knew from prior research that good trial results for any anti-cancer drug usually means big gains for the biotech's share price. Cancer is a disease area that garners a huge chunk of the total dollars spent annually on healthcare. Last year alone, patients spent a whopping $22 billion on cancer treatments. So, I dug a little deeper into the research behind TH-302... I discovered that TH-302 is a guided missile that zeroes in on cancerous tumors while avoiding healthy cells. The drug targets levels of hypoxia (low-oxygen concentration) common in tumors but rarely found in normal tissues. In other words, TH-302 attacks cancerous cells and avoids damaging healthy cells. I further discovered that TH-302 had performed well in early clinical testing. Patients treated with TH-302 saw big increases in both progression free survival and median overall survival compared to patients treated with an older chemotherapy. Armed with this knowledge, I recommended THLD to my subscribers on June 22, 2011. At the time, the stock was trading for just $1.63 per share. As it turns out, my diligent research paid off in spades! In early February, Threshold shocked the world with a major announcement. Merck KGaA agreed to pay Threshold up to $525 million in milestone payments for the opportunity to co-develop and co-market TH-302. At the time, Threshold was worth just over $63 million. As you might imagine, the stock soared on the news! It shot up 216% over the next two days. With the shares spiking, I told my subscribers to sell half their shares and pocket profits of 147%! But that was just the beginning... A couple of weeks later, Threshold released results from the phase 2 trial. The results showed patients taking TH-302 in combination with an older chemotherapy saw a 63% increase in progression free survival. And THLD soared again...  As you can see, the stock roared 88% higher in a single day. It even traded up to a four-year high of $6.65 per share. A few days later, I recommended selling the remaining half of our shares for gains of 278%! All in all, my subscribers more than tripled their money in just eight months' time. No question about it, biotechnology stocks are one of the few areas of the market that offer huge profit potential over short periods of time. But you can't just buy any old biotech and hope to rake in the dough. You really have to do your homework to find out which ones have the best chance of ultimately gaining FDA approval. And this research is not easy. Biotech companies are engaged in highly complicated scientific research. And the clinical trial process is an unforgiving gauntlet that leaves most drug candidates on the trash heap. If you'd like to grab your share of the huge potential profits in biotech stocks, I invite you to take a subscription to the Biotech Supertrader. You can learn all about it here. Plus, if you act now, you can get your subscription up and running before our next trade alert. We'll be recommending another high-quality biotech with huge upside potential next week! Profitably Yours, Robert Morris | Monday, February 27, 2012  • Alnylam Pharmaceuticals (ALNY) hit a new 52-week high of $13.75. The biotech's market cap is now over $586 million. • VIVUS (VVUS) set a new 52-week high of $23.78. They now have a market cap of just over $2.1 billion. • RadioShack (RSH) fell to a new 52-week low of $7.07. Their market cap is now down to $706 million.  "I dream of painting and then I paint my dream." -Vincent Van Gogh   
 Urgent Oil Market Update... Friday, February 24, 2012 Lin-Sanity Stock Picking! Wednesday, February 22, 2012 Insiders Are Buying Up FSYS… Friday, February 17, 2012    |
 Copyright 2012 Hyperion Financial Group, LLC. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This email may only be used pursuant to the subscription agreement controlling use of the Dynamic Wealth Report website and any reproduction, copying, or redistribution of this email or its contents, in whole or in part, is strictly prohibited without the express written permission of Hyperion Financial Group, LLC. LEGAL DISCLAIMER: Neither Hyperion Financial Group LLC nor any of its employees are a registered investment advisor or a Broker/Dealer. As such, Hyperion Financial Group, LLC does not offer or provide personalized investment advice. Although Hyperion Financial Group, LLC employees may answer general customer service questions, they are not licensed under securities laws to address your particular investment situation. Nothing in this report, nor any communication by our employees to you should be considered personalized investment advice. Owners and writers may have positions in the securities that are discussed. However, no associated employees may intentionally engage in any transaction that directly or indirectly competes with the interests of our subscribers. We accept no compensation from any companies mentioned in our reports. Past performance is no guarantee of future results. All information is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor is it to be construed as a recommendation to buy, hold or sell any security. All opinions, analyses and information contained herein are based on sources believed to be reliable and written in good faith, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. Investments recommended in this publication should only be made after consulting with your financial advisor. Any brokers mentioned herein constitute a partial list of available brokers and is for your information only. We do not recommend or endorse any brokers, dealers, or investment advisors. |
| This message was sent to ignoble.experiment@arconati.us from: Hyperion Financial | 20701 N Scottsdale Rd, Ste 107-154 | Scottsdale, AZ 85255 | Email Marketing by |
| Manage Your Subscription | Forward To a Friend |
No comments:
Post a Comment
Keep a civil tongue.